Danish Pharmacovigilance Update, 15 November 2012

In this issue of Danish Pharmacovigilance Update:

• Chlorhexidine and the risk of anaphylactic reaction (front page)
• Consumption and safety of cholesterol-lowering medicines (p 2)
• Benefits of NSAIDs continue to outweigh the potential risk of cardiovascular adverse reactions – however, the risk associated with diclofenac requires further investigation (p 3)
• The European Medicines Agency, EMA, is reviewing data on medicines containing codeine, especially concerning the use in children (p 3)
• Renal impairment in association with the use of ciclosporin (Sandimmun Neoral® and others) (p 4)
• Persons initiated on treatment with Champix® (varenicline) for smoking cessation should be prescribed the recommended starter pack containing starting doses (p 5)
• The Danish Health and Medicines Authority maintains influenza vaccine recommendation (p 5)
• Danish Pharmacovigilance Update celebrates its 3rd anniversary (p 6)